enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment
enVVeno Medical (NASDAQ:NVNO) announced that CEO Robert Berman will appear in a Live Virtual Investor CEO Connect segment on Wednesday, December 3, 2025 at 4:00 PM ET.
Rhea-AI Summary
enVVeno Medical (NASDAQ:NVNO) announced that CEO Robert Berman will appear in a Live Virtual Investor CEO Connect segment on Wednesday, December 3, 2025 at 4:00 PM ET. The moderated webcast will include a corporate overview, discussion of recent news and next steps, and a live Q&A where Mr. Berman will answer as many questions as time allows. A live video webcast will be available on the company Events page at www.envveno.com. A replay will be posted two hours after the live event and will remain accessible for 90 days.
Details
News Market Reaction – NVNO
On Nov 26, the day this news came out, NVNO closed 6.41% below the previous close.
Data tracked by StockTitan Argus for the Nov 26 session.
Key Figures
- Webcast time
- 4:00 PM ET
- Virtual Investor CEO Connect on December 3, 2025
- Replay availability
- 90 days
- Webcast replay access period after live event
- Cash & investments
- $31.5 million
- Reported at Q3 2025 end (Nov 13 regulatory update release)
- Quarterly cash burn
- $4–5 million
- Stated range supporting operations into 2027
- Q3 2025 net loss
- $4.5 million
- Three months ended September 30, 2025
- Prior-year net loss
- $5.6 million
- Three months ended September 30, 2024
- Kingdon stake
- 1,359,261 shares (7.1%)
- Passive holding disclosed in Schedule 13G on Sep 9, 2025
- 52-week range
- $0.3017–$5.62
- Pre‑news 52-week low and high for NVNO
Historical Context
-
Announcement of December 3 virtual investor CEO Connect webcast and Q&A.
-
Unfavorable FDA supervisory appeal decision upholding not‑approvable letter for VenoValve.
-
Q3 2025 results, cash runway into 2027, lower net loss, and regulatory update.
-
Virtual investor segment explaining supervisory appeal after VenoValve not‑approvable letter.
-
Plan to file supervisory appeal and highlight of large CVI patient population and timeline.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Wednesday, December 3rd at 4:00 PM ET
IRVINE, CA / ACCESS Newswire / November 26, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in a Live Virtual Investor CEO Connect segment on Wednesday, December 3, 2025 at 4:00 PM ET.
As part of the event, Mr. Berman will provide a corporate overview and discuss the Company's recent news and next steps. In addition to the moderated discussion, there will be a live question and answer session. Mr. Berman will answer as many questions as possible in the time allowed.
A live video webcast of the presentation will be available on the Events page of the Company's website (www.envveno.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.
About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease.
Cautionary Note on Forward-Looking Statements
This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
###
INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
NVNO@jtcir.com
(908) 824-0775
MEDIA CONTACT:
Glenn Silver, FINN Partners
Glenn.Silver@finnpartners.com
(973) 818-8198
SOURCE: enVVeno Medical Corporation
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.